Palbocare 75 Capsule contains Palbociclib 75 mg, a targeted anticancer medicine used in the treatment of certain types of hormone receptor-positive, HER2-negative breast cancer. It helps slow the growth and multiplication of cancer cells by targeting specific proteins involved in cell cycle regulation. The capsule is prescribed under the supervision of oncology specialists and is commonly used as part of advanced breast cancer treatment strategies.

Palbociclib belongs to the class of cyclin-dependent kinase (CDK) 4 and 6 inhibitors. It works by blocking the activity of proteins that promote cancer cell division, thereby helping arrest the growth of malignant cells and slowing disease progression. This targeted mechanism allows for more focused cancer treatment and has significantly improved therapeutic options for patients with specific forms of breast cancer.

The capsule is frequently prescribed in combination with hormonal therapies such as aromatase inhibitors or fulvestrant, depending on the patient's clinical condition and treatment requirements. It is primarily used in advanced or metastatic breast cancer where targeted therapy can provide meaningful disease control and improved treatment outcomes. Regular monitoring during therapy helps ensure effectiveness while managing potential treatment-related adverse effects.

With the increasing adoption of targeted oncology therapies and growing awareness of personalized cancer treatment, Palbocare 75 Capsule maintains strong demand in the oncology segment. Its proven clinical efficacy, established role in breast cancer management, and widespread acceptance among oncology professionals contribute to consistent market growth. The product offers valuable business opportunities and long-term potential for retailers and distributors operating within the oncology pharmaceutical sector.

Palbocare 75 Capsule may cause fatigue, nausea, diarrhea, stomatitis, hair thinning, decreased appetite, weakness, and infections. Low white blood cell counts, anemia, thrombocytopenia, fever, and increased susceptibility to infections may occur and require close medical supervision.

Palbocare 75 Capsule is indicated for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with appropriate hormonal therapy as determined by an oncology specialist. It helps slow cancer progression and supports comprehensive cancer management.

This medication should be used only under the supervision of a qualified healthcare professional experienced in oncology treatment. Regular monitoring of blood counts, liver function, and overall patient health is essential throughout therapy. Patients should immediately report fever, unusual bleeding, persistent infections, breathing difficulties, or other concerning symptoms. The dosage and treatment schedule should be followed exactly as prescribed by the treating oncologist.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the capsules in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of tampering.